| Identification | Back Directory | [Name]
4-amino-5-(tosyloxy)naphthalene-2,7-disulfonic acid | [CAS]
6837-93-0 | [Synonyms]
4-amino-5-(tosyloxy)naphthalene-2,7-disulfonic acid
1-Amino-8-(4-methylphenylsulfonyloxy)naphthalene-3,6-disulfonic acid
8-Amino-1-(4-methylphenylsulfonyloxy)-3,6-naphthalenedisulfonic acid
4-amino-5-(4-methylphenyl)sulfonyloxynaphthalene-2,7-disulfonic acid
4-Amino-5-[[(4-methylphenyl)sulfonyl]oxy]-2,7-naphthalenedisulfonic acid
2,7-Naphthalenedisulfonic acid, 4-amino-5-[[(4-methylphenyl)sulfonyl]oxy]- | [Molecular Formula]
C17H15NO9S3 | [MOL File]
6837-93-0.mol | [Molecular Weight]
473.5 |
| Chemical Properties | Back Directory | [density ]
1.5197 (rough estimate) | [refractive index ]
1.7000 (estimate) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 31.25 mg/mL (66.00 mM) | [form ]
Solid | [pka]
-1.16±0.40(Predicted) | [color ]
Off-white to gray |
| Hazard Information | Back Directory | [Uses]
NSC16168 is a specific inhibitor of ERCC1-XPF, with an IC50 value of 0.42 μM. NSC16168 inhibits DNA repair and potentiates CDDP efficacy in cancer[1]. | [Biological Activity]
NSC16168 is a specific ERCC1-XPF inhibitor with IC50 value of 0.42 μM. It inhibits DNA repair and enhances the efficacy of CDDP in cancer. | [in vitro]
NSC16168 (0-50 μM) potentiates cisplatin efficacy in cancer cells.
Cell Viability Assay. < td class="col1"> Cell Line: | H460 cells. | | Concentration: | 0-50 μM. | | Incubation Time: | 2 h. | | Result: | Potentiated cisplatin efficacy in cancer cells. | table> [in vivo]
NSC16168 (20 mg/kg, ip, twice daily) exhibits significant anti-tumor activity and potentiates cisplatin antitumor activity in H460 lung cancer xenografts.
< /b> | Animal Model: | 2.5×10 6 H460 cells were injected sc in the right flank of each mouse.
| | Dosage: | 20 mg/kg. | | Administration: | IP, twice daily for 10 days. | | Result: | The tumor growth was minimally affected by compound and the mice displayed no signs of distress or toxic side effects.
The combination treatment with 16168 and cisplatin inhibited H460 tumor growth, which was maintained for the duration of the compound injections. | | [target]
IC50: 0.42 μM (ERCC1-XPF). | [References]
[1] Arora S, et al. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Oncotarget. 2016 Nov 15;7(46):75104-75117. DOI:10.18632/oncotarget.12072 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|
|
Tags:6837-93-0
Related Product Information
|
|
|
|